A Phase 2, Open Label Study to Evaluate Vimseltinib in Adults with Active Chronic Graft-Versus-Host Disease after Failure of Prior Systemic Therapies

Key Points

• Vimseltinib shows promise for treating chronic graft-versus-host disease in adults.
• The primary measure of success is based on symptom improvement after previous treatment failures.
• Phase 2 study design assesses efficacy and safety of vimseltinib in adults with chronic graft-versus-host disease.
• The findings may lead to improved therapeutic options for patients who do not respond to existing therapies.